Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Gains from Investment Securities (2022 - 2025)

NewAmsterdam Pharma's Gains from Investment Securities history spans 4 years, with the latest figure at $29.6 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 6832.08% year-over-year to $29.6 million; the TTM value through Dec 2025 reached $23.6 million, up 491.53%, while the annual FY2025 figure was $59.9 million, 214.78% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $29.6 million at NewAmsterdam Pharma, up from $22.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $29.6 million in Q4 2025 and bottomed at -$7.4 million in Q3 2024.
  • The 4-year median for Gains from Investment Securities is $3.7 million (2025), against an average of $7.4 million.
  • The largest annual shift saw Gains from Investment Securities crashed 564.88% in 2024 before it surged 6832.08% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $11.4 million in 2022, then crashed by 85.93% to $1.6 million in 2023, then plummeted by 73.31% to $427000.0 in 2024, then soared by 6832.08% to $29.6 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Gains from Investment Securities are $29.6 million (Q4 2025), $22.2 million (Q2 2025), and $3.7 million (Q1 2025).